Compare GSK plc (GSK) vs Meta Platforms Inc (META) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Meta Platforms Inc — how do they compare? GSK plc trades at $46.52 (market cap $91.88B), while Meta Platforms Inc trades at $717.9 (market cap $1.84T). The key difference: Meta Platforms Inc is far larger — about 20× GSK plc's market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Meta Platforms Inc for 127 Days on average.
| GSK | META | |
|---|---|---|
Market Cap | $91.88B | $1.84T |
Volume | 7,730,529 | 15,887,049 |
Sector | Health | Media |
52-Week High | $61.18 | $777.59 |
52-Week Low | $43.24 | $525.72 |
Typical Hold Time | 93 Days | 127 Days |
Enterprise Value | $111.88B | $1.86T |
Dividend Yield | 3.9% | 0.29% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.50, down 1.11% with bearish technical signals, though RSI levels suggest potential oversold conditions. Fundamentally, the company shows strong profitability with 72.73% gross margins and consistent earnings beats, while maintaining a reasonable P/E of 14.89. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite facing an HIV patent cliff.
GSK presents a mixed investment case with strong fundamentals and pipeline growth offset by technical weakness and patent expiration risks. The company's £40B sales target and cost-saving initiatives provide upside potential, while analyst consensus leans cautious with 55% hold ratings. Key risks include execution of pipeline development and competitive pressures in core markets.
META trades at $718.67, down 0.37% on the day, with a bullish technical signal supported by moving averages. The company reported strong revenue growth to $201B in 2025 and maintains robust profitability with 29.84% net margins. Recent AI developments, including the Muse Spark launch, and a $21B deal with CoreWeave highlight strategic positioning. Analyst consensus is strongly bullish with an 80% buy rating and $781 price target, though legal challenges and high capital expenditures present headwinds.
META's outlook remains positive driven by AI innovation and solid fundamentals, but investors face risks from regulatory lawsuits and volatile tech sentiment. The stock offers upside to consensus targets if execution continues, yet high valuation multiples and market rotation pressures warrant caution. Balancing growth prospects with legal and competitive risks is key for medium-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Meta Platforms Inc
Meta Platforms Inc., doing business as Meta and previously known as Facebook Inc. It's a company that acts as a parent platform for Facebook, Messenger, Instagram, Whatsapp, Oculus and other subsidiaries. Among these platforms, Facebook is the number one social media platform in terms of the number of active users.
Read more on META →
